Kodiak Sciences Inc.

NasdaqGM:KOD Stock Report

Market Cap: US$344.4m

Kodiak Sciences Valuation

Is KOD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KOD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KOD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KOD's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for KOD?

Key metric: As KOD is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for KOD. This is calculated by dividing KOD's market cap by their current book value.
What is KOD's PB Ratio?
PB Ratio1.9x
BookUS$185.37m
Market CapUS$344.41m

Price to Book Ratio vs Peers

How does KOD's PB Ratio compare to its peers?

The above table shows the PB ratio for KOD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.3x
LXRX Lexicon Pharmaceuticals
1.6x18.6%US$296.5m
CMPS COMPASS Pathways
1.6x9.8%US$309.3m
DSGN Design Therapeutics
1.3x-17.7%US$348.2m
ITOS iTeos Therapeutics
0.5x8.5%US$299.2m
KOD Kodiak Sciences
1.9x-7.0%US$344.4m

Price-To-Book vs Peers: KOD is expensive based on its Price-To-Book Ratio (1.9x) compared to the peer average (1.3x).


Price to Book Ratio vs Industry

How does KOD's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$588.69m
AMRN Amarin
0.4x-7.7%US$205.50m
IMAB I-Mab
0.4x1.8%US$77.18m
MGX Metagenomi
0.3x-23.2%US$75.22m
KOD 1.9xIndustry Avg. 1.9xNo. of Companies73PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: KOD is good value based on its Price-To-Book Ratio (1.9x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is KOD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KOD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KOD's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KOD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.55
US$4.33
-33.8%
34.4%US$6.00US$2.00n/a6
Nov ’25US$3.84
US$2.75
-28.4%
15.7%US$3.00US$2.00n/a4
Oct ’25US$2.60
US$2.75
+5.8%
15.7%US$3.00US$2.00n/a4
Sep ’25US$2.51
US$2.67
+6.2%
17.7%US$3.00US$2.00n/a3
Aug ’25US$2.89
US$3.50
+21.1%
31.9%US$5.00US$2.00n/a4
Jul ’25US$2.37
US$3.50
+47.7%
31.9%US$5.00US$2.00n/a4
Jun ’25US$3.18
US$3.50
+10.1%
31.9%US$5.00US$2.00n/a4
May ’25US$3.53
US$4.25
+20.4%
45.2%US$7.00US$2.00n/a4
Apr ’25US$4.45
US$3.75
-15.7%
51.2%US$7.00US$2.00n/a4
Mar ’25US$6.01
US$2.63
-56.3%
24.7%US$3.50US$2.00n/a4
Feb ’25US$4.39
US$4.50
+2.5%
84.3%US$12.00US$2.00n/a5
Jan ’25US$3.04
US$4.40
+44.7%
87.0%US$12.00US$2.00n/a5
Dec ’24US$2.57
US$5.25
+104.3%
75.4%US$12.00US$2.00n/a4
Nov ’24US$1.54
US$4.00
+159.7%
46.8%US$7.00US$2.00US$3.844
Oct ’24US$1.80
US$4.00
+122.2%
46.8%US$7.00US$2.00US$2.604
Sep ’24US$2.40
US$4.00
+66.7%
46.8%US$7.00US$2.00US$2.514
Aug ’24US$3.00
US$5.20
+73.3%
56.3%US$10.00US$2.00US$2.895
Jul ’24US$6.90
US$11.25
+63.0%
54.4%US$24.00US$4.00US$2.378
Jun ’24US$6.35
US$11.25
+77.2%
54.4%US$24.00US$4.00US$3.188
May ’24US$4.54
US$11.25
+147.8%
54.4%US$24.00US$4.00US$3.538
Apr ’24US$6.20
US$11.75
+89.5%
49.6%US$24.00US$5.00US$4.458
Mar ’24US$6.40
US$11.75
+83.6%
49.6%US$24.00US$5.00US$6.018
Feb ’24US$8.23
US$12.70
+54.3%
44.0%US$24.00US$5.00US$4.3910
Jan ’24US$7.16
US$12.70
+77.4%
44.0%US$24.00US$5.00US$3.0410
Dec ’23US$7.29
US$12.70
+74.2%
44.0%US$24.00US$5.00US$2.5710
Nov ’23US$7.09
US$12.22
+72.4%
32.0%US$18.00US$5.00US$1.549

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies